Q32 Bio Inc. 8-K Filing

FAQ

Key Financial Figures

• $0.0001 — ich registered Common stock, par value $0.0001 per share QTTB The Nasdaq Capital M
• $7.0 million — pany (i) received an upfront payment of $7.0 million on the Closing Date, and (ii) will rece
• $3.0 million — ate, and (ii) will receive a payment of $3.0 million on the six-month anniversary of the Clo
• $2.0 million — eceive a near-term milestone payment of $2.0 million upon the earlier of achievement of the
• $580 million — he Company is eligible to receive up to $580 million upon the achievement of specified miles
• $92.5 million — f specified milestones, including up to $92.5 million related to development and regulatory m
• $487.5 million — ent and regulatory milestones and up to $487.5 million related to commercial milestones. The C
• $5.0 million — th the $7.0 million upfront payment and $5.0 million in anticipated near-term milestone paym

Filing Documents

• d70163d8k.htm (8-K) — 36KB
• d70163dex991.htm (EX-99.1) — 15KB
• g70163g1129054949920.jpg (GRAPHIC) — 3KB
• 0001193125-25-303115.txt ( ) — 172KB
• qttb-20251128.xsd (EX-101.SCH) — 3KB
• qttb-20251128_lab.xml (EX-101.LAB) — 17KB
• qttb-20251128_pre.xml (EX-101.PRE) — 11KB
• d70163d8k_htm.xml (XML) — 3KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, statements relating to the Company's expectations that its cash and cash equivalents, together with the $7.0 million upfront payment and $5.0 million in anticipated near-term milestone payments from the ADX-097 Asset Sale, are expected to fund the Company's operations into the second half of 2027, are forward-looking statements. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions among others. Forward-looking statements are based on management's current beliefs and assumptions, which are subject to risks and uncertainties and are not guarantees of future performance. Such risks and uncertainties include, among others, the risk that actual results may differ from the Company's projected cash runway, and such other risks and uncertainties identified in the Company's periodic, current and other filings with the U.S. Securities and Exchange Commission (the "SEC"), including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and any subsequent filings with the SEC, which are available at the SEC's website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect the Company's results of operations and its cash flows, which would, in turn, have a significant and adverse

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued on December 1, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Q32 BIO INC. Date: December 1, 2025 By: /s/ Jodie Morrison Name: Title: Jodie Morrison Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR